ESMO Breast Cancer 2019: Industry Participation

ESMO Breast Cancer 2019 will have a truly comprehensive programme with leading global experts speaking on thought-provoking topics. 

Several sessions will ensure a thorough discussion of all key issues in both early and metastatic breast cancer. The programme will feature advanced educational sessions on the latest in personalized medicine and translational oncology. New developments in immuno-oncology and other innovative treatments across subtypes are also among our key highlights.

The ESMO Breast Cancer programme will touch on every important issue and controversy debated in breast cancer today.

Fast Facts: ESMO Breast Cancer 2019

  • Expecting over 800 participants
  • 4 parallel sessions
  • Possibility to host 13 satellite symposia
  • More than 80 international faculty
  • Excellent networking opportunities

How can I participate at ESMO Breast Cancer 2019?

At ESMO we are committed to providing our industry partners with a variety of solutions to facilitate their presence at our congress. 

For sponsorship information and a prospectus please contact:

Jon Roberts
Head of Strategic Partnerships
jon.roberts@esmo.org

We look forward to hearing from you!

Official Italian agency for AIFA procedure

AIFA rules are mandatory only for Italian Pharmaceutical Companies that will attend a congress abroad.

Any pharmaceutical company supporting or participating in a congress, is subjected to an authorisation by AIFA (Italian Drug Agency), according to an Italian Government Decree (Decreto Legislativo 219/06 – art. 124). The request of authorisation must be submitted within 60 days before the starting date of the event.

ESMO advises pharmaceutical companies to contact the Official Agency:

AIM Group International – AIM Education S.r.l.
Contact: Valentina Disabato/ Crisitina Ghidoli
Via G. Ripamonti, 129
20141 Milan – Italy
Tel.: +39 02 56601 1
Fax.: +39 02 70048585
E-mail: aifa@aimgroup.eu

Preparatory Information

To get up to speed with your preparation for ESMO Breast Cancer 2019, please download our Industry Guidelines below